Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

A Phase I Study to Compare 3 Different Strengths of an Extended Release Formulation of ASP015K to an Immediate Release Formulation of ASP015K

This study has been completed.
Information provided by (Responsible Party):
Astellas Pharma Inc ( Astellas Pharma Global Development, Inc. ) Identifier:
First received: September 6, 2012
Last updated: August 31, 2015
Last verified: August 2015
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: July 2012
  Primary Completion Date: July 2012 (Final data collection date for primary outcome measure)